Home / Deep Research / Pseudoxanthoma Elasticum

Pseudoxanthoma Elasticum

1. Disease Information

2026-06-18
Falcon MONDO:0100091 Model: Edison Scientific Literature 32 citations

1. Disease Information

Disease Definition and Overview

Pseudoxanthoma elasticum (PXE; OMIM #264800) is a rare, genetic, autosomal recessive metabolic disease characterized by progressive ectopic mineralization affecting elastic tissues in the skin, eyes, and cardiovascular system (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2). The disease manifests with deposition of calcium hydroxyapatite crystals that accumulate in the mid-dermal elastic fibers, Bruch's membrane of the eye, and arterial blood vessels (luo2020therapeuticsdevelopmentfor pages 1-3, kauffenstein2024thepurinergicnature pages 1-2). PXE is the prototype of heritable ectopic mineralization disorders, distinguished by its multisystem clinical manifestations that usually appear around the second decade of life (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 1-2).

Key Identifiers

Data Source Classification

Information is derived from aggregated disease-level resources including peer-reviewed clinical studies, systematic reviews, case series, and controlled clinical trials in PXE patient cohorts, complemented by animal model research and cellular studies (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, kranenburg2018etidronateforprevention pages 1-2).

2. Etiology

Disease Causal Factors

PXE is a genetic disorder caused by mutations in the ABCC6 gene (ATP-binding cassette subfamily C member 6), discovered in 2000 (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5). The ABCC6 gene is located on chromosome 16p13.11 and consists of 31 exons encoding a 1503-amino acid protein (molecular weight approximately 165–170 kDa) (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5). ABCC6 functions as an ATP-dependent transmembrane efflux transporter expressed predominantly in the liver and kidneys (stumpf2021therapyofpseudoxanthoma pages 1-2, kauffenstein2024thepurinergicnature pages 1-2, verschuere2020frommembraneto pages 1-5). Although the precise substrate(s) of ABCC6 remain uncertain, it facilitates the cellular efflux of ATP, which is sequentially hydrolyzed by ectonucleotidases ENPP1 and CD73 into pyrophosphate (PPi) and adenosine, both potent endogenous inhibitors of calcification (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).

The unifying pathomechanistic feature of PXE is reduced plasma levels of inorganic pyrophosphate (PPi), a powerful anti-mineralization factor. ABCC6 deficiency leads to approximately 60% reduction in plasma PPi levels in both humans and mice (leftheriotis2022relationshipsbetweenplasma pages 1-2, zedde2025abcc6involvementin pages 1-2, verschuere2020frommembraneto pages 8-10). This PPi deficiency results in an imbalance of the physiological Pi/PPi ratio in connective tissues, promoting ectopic calcification (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).

Risk Factors

Genetic Risk Factors: - Biallelic pathogenic variants in ABCC6 are the primary genetic cause. Over 300 distinct loss-of-function mutations have been reported, with recurrent variants p.R1141X and g.del23-29 accounting for up to ~45% of all pathogenic mutations (li2019pseudoxanthomaelasticumas pages 1-6, marconi2015pseudoxanthomaelasticumand pages 1-2, plumers2023matrixmetalloproteinasescontribute pages 1-2). - Variant types include missense, nonsense, frameshift, splice-site mutations, and structural rearrangements (deletions, duplications) (marconi2015pseudoxanthomaelasticumand pages 1-2, verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5). - Rare modifier variants in genes related to calcium homeostasis, vascular disease, apoptosis, and purinergic signaling (e.g., NLRP1, SELE, TRPV1, CSF1R) may alter cardiovascular disease severity (vilder2021raremodifiervariants pages 1-2). - Heterozygous carriers of ABCC6 mutations may have an increased risk of cardiovascular calcification and premature coronary artery disease, although classic PXE typically requires biallelic pathogenic variants (germain2017pseudoxanthomaelasticum pages 2-4, germain2017pseudoxanthomaelasticum pages 4-5).

Environmental Risk Factors: - Age is a major determinant of disease severity and calcification burden; time (i.e., age) appears to be the principal driver of progressive arterial calcification independent of plasma PPi levels (leftheriotis2022relationshipsbetweenplasma pages 1-2). - Traditional cardiovascular risk factors such as smoking, dyslipidemia, and hypertension may additively worsen vascular complications (stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2).

Protective Factors

Specific genetic protective factors have not been definitively established in retrieved literature. However, higher serum magnesium levels were associated with higher serum calcification propensity T50 (indicative of lower calcification risk), suggesting magnesium may have a protective role (nollet2022serumcalcificationpropensity pages 1-2). Lifestyle modifications reducing cardiovascular risk factors are recommended as supportive measures but do not reverse underlying mineralization (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2).

Gene-Environment Interactions

PXE pathophysiology reflects a complex interplay between genetic ABCC6 deficiency and environmental/age-related factors. While ABCC6 mutations cause systemic PPi deficiency, environmental contributors such as dietary phosphate, oxidative stress, and aging accelerate or modulate the mineralization process (germain2017pseudoxanthomaelasticum pages 4-5). Specific gene-environment interaction data are limited in retrieved studies.

3. Phenotypes

Table (click to expand)
Organ System Specific Manifestation Age of Onset Frequency in PXE Patients Severity Progression Pattern HPO Terms (suggested) Quality of Life Impact
Integumentary / Skin Small yellow papules on neck and flexural areas Typically childhood to adolescence; often first clinical sign (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4) Common / usually initial presenting sign; “almost always” first clinical sign in review literature (germain2017pseudoxanthomaelasticum pages 1-2) Usually mild medically, cosmetically significant Progressive: isolated papules coalesce into plaques over time (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4) HP:0000987 Skin papule; HP:0010783 Abnormality of the skin of the neck; HP:0000978 Bruising susceptibility not applicable; HP:0001065 Generalized lax skin not initial Cosmetic burden; may cause distress and social/self-image impact, but usually less disabling than ocular/vascular disease (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2)
Integumentary / Skin Lax, wrinkled, redundant skin in flexural areas Usually follows papules, often from adolescence/early adulthood onward (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4) Common in established disease; qualitative frequency high in clinical descriptions (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3) Mild to moderate Progressive chronic change with loss of recoil and leathery/sagging skin (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4) HP:0000973 Wrinkled skin; HP:0001007 Redundant skin; HP:0001513 Cutis laxa-like skin changes Mainly cosmetic and psychosocial impact; may affect body image and clothing comfort (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2)
Ophthalmologic Peau d’orange / early Bruch’s membrane change Often precedes angioid streaks; can occur in young patients Observed in 96% of patients with skin signs in one study cited by review (germain2017pseudoxanthomaelasticum pages 2-4) Usually mild initially Early marker that may precede more vision-threatening retinal disease (germain2017pseudoxanthomaelasticum pages 2-4, risseeuw2020areflectivitymeasure pages 1-2) HP:0030937 Abnormality of Bruch membrane; HP:0100012 Retinal abnormality Usually limited direct impact initially, but clinically important as precursor of later visual morbidity (germain2017pseudoxanthomaelasticum pages 2-4, risseeuw2020areflectivitymeasure pages 1-2)
Ophthalmologic Angioid streaks Usually years after skin changes; often early adult life (germain2017pseudoxanthomaelasticum pages 2-4) Characteristic ocular feature; common in affected adults (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4) Moderate to severe because of risk of CNV and vision loss Progressive; may become symptomatic when approaching fovea (germain2017pseudoxanthomaelasticum pages 2-4) HP:0007932 Angioid streaks of the fundus Major threat to vision; central visual tasks and reading/driving may become impaired (germain2017pseudoxanthomaelasticum pages 2-4)
Ophthalmologic Choroidal neovascularization (CNV) Usually after angioid streaks, often adulthood Common complication of calcified Bruch’s membrane in progressing disease; exact percentage not given in retrieved sources (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3) Severe Progressive/episodic with hemorrhage and scarring if untreated (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4) HP:0007754 Choroidal neovascularization High impact; anti-VEGF treatment burden and risk of central vision loss reduce daily functioning (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3)
Ophthalmologic Progressive loss of visual acuity / central vision loss / blindness in late-stage disease Often adulthood, with severe impairment potentially by 40s if untreated (luo2020therapeuticsdevelopmentfor pages 1-3) Important late complication; exact prevalence not provided in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3) Severe Progressive due to hemorrhage, scarring, and macular atrophy (luo2020therapeuticsdevelopmentfor pages 1-3, risseeuw2020areflectivitymeasure pages 1-2) HP:0000505 Visual impairment; HP:0000529 Progressive visual loss; HP:0000618 Blindness Very high impact; vision-related quality of life is markedly reduced, and visual impairment was associated with major degradation in vision-related QoL (germain2017pseudoxanthomaelasticum pages 2-4)
Cardiovascular / Vascular Arterial calcification (including lower-limb and coronary calcification) Usually becomes apparent years after skin/ocular changes; increases with age (leftheriotis2022relationshipsbetweenplasma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4) Common hallmark in adult PXE; severity strongly age-dependent (leftheriotis2022relationshipsbetweenplasma pages 1-2, kranenburg2018etidronateforprevention pages 1-2) Moderate to severe Progressive, chronic, age-related accumulation; major determinant appears to be time/age (leftheriotis2022relationshipsbetweenplasma pages 1-2) HP:0004958 Arterial calcification; HP:0005117 Vascular calcification Contributes to vascular morbidity, reduced exercise capacity, and anxiety about cardiovascular events (stumpf2021therapyofpseudoxanthoma pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2)
Cardiovascular / Vascular Peripheral artery disease (PAD) Typically adulthood after earlier skin/eye findings (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4) Major cause of morbidity; common qualitative feature (leftheriotis2022relationshipsbetweenplasma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4) Moderate to severe Progressive chronic vascular disease; may require intervention in advanced stages (vilder2021raremodifiervariants pages 1-2) HP:0004939 Peripheral arterial insufficiency Limits walking and physical activity; contributes to reduced participation in social/occupational activities (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)
Cardiovascular / Vascular Intermittent claudication Usually adulthood Cardinal symptom of lower-extremity arterial disease; common qualitative feature (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4) Moderate Progressive with worsening PAD; exertional symptom burden (luo2020therapeuticsdevelopmentfor pages 1-3, germain2017pseudoxanthomaelasticum pages 2-4) HP:0002579 Intermittent claudication Substantial mobility limitation and exercise intolerance; important contributor to reduced QoL (stumpf2021therapyofpseudoxanthoma pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4)
Cardiovascular / Vascular Hypertension Usually adulthood Reported but less consistently emphasized than calcification/PAD; exact percentage not provided (luo2020therapeuticsdevelopmentfor pages 1-3, plumers2023matrixmetalloproteinasescontribute pages 1-2) Mild to moderate, can contribute to vascular risk Chronic; may coexist with arterial disease (plumers2023matrixmetalloproteinasescontribute pages 1-2) HP:0000822 Hypertension Adds long-term cardiovascular risk and treatment burden (luo2020therapeuticsdevelopmentfor pages 1-3, plumers2023matrixmetalloproteinasescontribute pages 1-2)
Neurologic / Cerebrovascular Ischemic stroke risk / cerebrovascular disease Usually older adults; risk appears elevated relative to general population (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2) 15% in one cohort of 38 PXE patients; 7% in another cohort of 100, relative risk 3.6 vs general population (germain2017pseudoxanthomaelasticum pages 2-4) Severe Episodic vascular complication on background of progressive vasculopathy (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2) HP:0002140 Ischemic stroke; HP:0001297 Cerebrovascular accident Potentially devastating disability; major anxiety source and contributor to long-term morbidity (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2)
Gastrointestinal Gastrointestinal bleeding (especially stomach) Usually adulthood Around 15% of PXE patients vs ~0.1% in general population, according to review summary (germain2017pseudoxanthomaelasticum pages 2-4) Moderate to severe; potentially acute Episodic complication HP:0002239 Gastrointestinal hemorrhage; HP:0002573 Hematemesis if present Acute morbidity, hospitalization risk, and anxiety regarding bleeding events (germain2017pseudoxanthomaelasticum pages 2-4)

Table: This table summarizes the major clinical manifestations of pseudoxanthoma elasticum across skin, ocular, vascular, neurologic, and gastrointestinal systems. It highlights onset, frequency, progression, suggested HPO annotations, and likely quality-of-life effects for knowledge base curation.

The table above summarizes the major clinical manifestations across organ systems. Key phenotypes include:

Cutaneous Manifestations

Ophthalmological Manifestations

Cardiovascular and Vascular Manifestations

Gastrointestinal Manifestations

Quality of Life Impact

Visual impairment is associated with major degradation in vision-related quality of life measured by the Impact of Vision Impairment questionnaire (germain2017pseudoxanthomaelasticum pages 2-4). Cardiovascular complications have relatively less measured impact on health-related QoL according to SF-36 surveys, though intermittent claudication significantly limits mobility and social/occupational participation (germain2017pseudoxanthomaelasticum pages 2-4, stumpf2021therapyofpseudoxanthoma pages 1-2).

4. Genetic/Molecular Information

Table (click to expand)
Gene Name Gene Symbol Chromosome Location Protein Name Protein Size Protein Function Common Pathogenic Variants Variant Types Mode of Inheritance Penetrance Key Molecular Pathways
ATP-binding cassette subfamily C member 6 ABCC6 16p13.11 / 16p13.1 ABCC6 / MRP6 1503 aa, ~165–170 kDa glycoprotein ATP-dependent transmembrane efflux transporter, expressed predominantly in liver and kidney; promotes extracellular ATP efflux, which is converted by ENPP1 and CD73 to PPi and adenosine; major upstream regulator of anti-mineralization homeostasis (verschuere2020frommembraneto pages 1-5, germain2017pseudoxanthomaelasticum pages 1-2, verschuere2020frommembraneto pages 8-10, kauffenstein2024thepurinergicnature pages 1-2) Recurrent loss-of-function variants include p.R1141X and del23-29 / g.del23-29, together accounting for up to ~45% of pathogenic alleles in some cohorts; >300 variants reported overall, now ~400 in newer summaries (li2019pseudoxanthomaelasticumas pages 1-6, marconi2015pseudoxanthomaelasticumand pages 1-2, plumers2023matrixmetalloproteinasescontribute pages 1-2) Missense, nonsense, splice-site, small insertions/deletions, multiexon deletions/structural variants; predominantly loss-of-function (marconi2015pseudoxanthomaelasticumand pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5, verschuere2020frommembraneto pages 8-10) Autosomal recessive PXE; ABCC6 variants can also cause some GACI type 2 cases (germain2017pseudoxanthomaelasticum pages 1-2, jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) Generally high for biallelic pathogenic variants with age-dependent and variable expressivity; heterozygotes usually unaffected but may show subclinical or partial manifestations and elevated vascular calcification risk in some reports (germain2017pseudoxanthomaelasticum pages 4-5, germain2017pseudoxanthomaelasticum pages 2-4) ABCC6 → extracellular ATP efflux → ENPP1 → PPi + AMP → CD73/NT5E → adenosine; TNAP opposes PPi by hydrolysis; purinergic signaling / Pi:PPi balance / ectopic calcification inhibition (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2, verschuere2020frommembraneto pages 8-10)
Ectonucleotide pyrophosphatase/phosphodiesterase 1 ENPP1 Not specified in retrieved PXE contexts ENPP1 / NPP1 Not specified in retrieved PXE contexts Principal ectoenzyme generating extracellular PPi from ATP; core anti-calcification enzyme downstream of ABCC6. ENPP1 deficiency causes classic GACI, and some ENPP1-mutated patients can present PXE-like features or overlap phenotypes (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, kauffenstein2024thepurinergicnature pages 1-2) Specific recurrent ENPP1 variants were not detailed in retrieved PXE contexts; disease-causing ENPP1 variants underlie most classic GACI and can overlap phenotypically with PXE (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) Loss-of-function variants, including missense, nonsense, splice, and other disruptive alleles causing reduced/absent ENPP1 activity; exact spectrum not detailed in retrieved contexts (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) Autosomal recessive for GACI; overlap with PXE spectrum recognized (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) High for biallelic ENPP1 deficiency, but phenotype may range from severe infantile vascular calcification to PXE-like overlap; detailed penetrance not specified in retrieved contexts (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) Extracellular ATP hydrolysis to AMP + PPi; central PPi-generating step in the ABCC6–ENPP1–CD73–TNAP pathway regulating ectopic mineralization (kauffenstein2024thepurinergicnature pages 1-2, jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2)
5'-nucleotidase ecto / CD73 NT5E Not specified in retrieved PXE contexts CD73 Not specified in retrieved PXE contexts Converts AMP to adenosine in the extracellular space; adenosine indirectly inhibits calcification, in part by suppressing TNAP, thereby preserving PPi-mediated anti-calcification effects (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) Specific recurrent NT5E pathogenic variants were not detailed in retrieved PXE contexts; NT5E mutations cause CALJA/ACDC, an overlapping ectopic calcification disorder (kauffenstein2024thepurinergicnature pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) Loss-of-function variants causing reduced/absent CD73 activity; exact variant spectrum not detailed in retrieved contexts (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) Autosomal recessive for CALJA/ACDC; part of the PXE–GACI–CALJA disease continuum (kauffenstein2024thepurinergicnature pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) Detailed penetrance not specified in retrieved PXE contexts; phenotype is generally adult/late-onset in CALJA compared with PXE and GACI (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) AMP → adenosine, with downstream reduction of TNAP activity and support of anti-mineralization purinergic signaling; final shared branch of the ABCC6–ENPP1–CD73–TNAP axis (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2)

Table: This table summarizes the core genes and pathway biology relevant to pseudoxanthoma elasticum and related PPi-deficiency calcification disorders. It highlights ABCC6 as the primary PXE gene and places ENPP1 and NT5E within the shared extracellular ATP-PPi-adenosine anti-mineralization pathway.

Causal Genes and Pathogenic Variants

The primary causal gene is ABCC6 (OMIM *603234), located on chromosome 16p13.11 (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5). The gene encodes a 1503-amino acid transmembrane protein predominantly expressed in hepatocytes and renal tissues (verschuere2020frommembraneto pages 1-5, verschuere2020frommembraneto pages 8-10). More than 300–400 distinct pathogenic variants have been identified, including:

Variant Classification: Most ABCC6 variants are classified as pathogenic or likely pathogenic loss-of-function alleles per ACMG/AMP guidelines. Functional studies in HEK293 cells and patient fibroblasts support loss-of-function consequences (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5).

Allele Frequency: PXE is rare, with estimated carrier frequency up to 1 in 80 for heterozygous ABCC6 mutations in the general population (germain2017pseudoxanthomaelasticum pages 2-4).

Germline vs Somatic: All reported PXE-causing ABCC6 variants are germline (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5).

Related Genes

ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1): Mutations cause classic GACI (Generalized Arterial Calcification of Infancy), and some ENPP1-deficient patients present PXE-like features (luo2020therapeuticsdevelopmentfor pages 1-3, jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2).

NT5E (CD73): Mutations cause CALJA/ACDC (Calcification of Joints and Arteries / Arterial Calcification Due to CD73 Deficiency), part of the ectopic mineralization disease continuum (kauffenstein2024thepurinergicnature pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2).

Modifier Genes

Rare modifier variants in genes involved in calcium homeostasis (e.g., TRPV1), vascular disease (e.g., SELE, CSF1R), and apoptosis (e.g., NLRP1) may collectively influence cardiovascular phenotype severity through IL-1B signaling pathways (vilder2021raremodifiervariants pages 1-2).

Epigenetic Information

Limited specific epigenetic data are available in retrieved PXE literature. Oxidative stress has been shown to inhibit ABCC6 gene expression in human cell lines, suggesting possible environmental or epigenetic modulation (germain2017pseudoxanthomaelasticum pages 4-5).

Chromosomal Abnormalities

The ABCC6 locus on 16p13.11 is prone to genomic rearrangements due to abundance of repetitive elements and flanking pseudogenes (ABCC6-Ψ1 and ABCC6-Ψ2) with ~99% sequence identity to the functional gene (verschuere2020frommembraneto pages 8-10).

5. Environmental Information

Environmental Factors

PXE is primarily a genetic disorder. However, oxidative stress from iron overload (as seen in β-thalassemia) can induce PXE-like syndrome, suggesting environmental oxidative damage may interact with genetic susceptibility (germain2017pseudoxanthomaelasticum pages 4-5).

Lifestyle Factors

Smoking, diet, and traditional cardiovascular risk factors (dyslipidemia, hypertension) may additively worsen vascular complications, although they do not directly cause PXE (stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2).

Infectious Agents

Not applicable; PXE is not caused by infectious agents.

6. Mechanism / Pathophysiology

Molecular Pathways

The central pathophysiological pathway in PXE is the ABCC6 → extracellular ATP → ENPP1 → PPi + AMP → CD73 → adenosine purinergic cascade (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2, verschuere2020frommembraneto pages 8-10):

  1. ABCC6 facilitates ATP efflux from hepatocytes into the extracellular space (kauffenstein2024thepurinergicnature pages 1-2, verschuere2020frommembraneto pages 8-10).
  2. ENPP1 hydrolyzes extracellular ATP to AMP and PPi (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).
  3. CD73/NT5E converts AMP to adenosine (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).
  4. PPi directly inhibits hydroxyapatite crystal nucleation and growth (shimada2021abcc6pyrophosphateand pages 1-2).
  5. Adenosine indirectly inhibits calcification by suppressing tissue non-specific alkaline phosphatase (TNAP), which degrades PPi (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2).

ABCC6 deficiency reduces plasma PPi by approximately 60% in humans and mice, lowering the Pi/PPi ratio and permitting ectopic mineralization (leftheriotis2022relationshipsbetweenplasma pages 1-2, zedde2025abcc6involvementin pages 1-2, verschuere2020frommembraneto pages 8-10).

Cellular Processes

GO Terms: GO:0030574 (collagen catabolic process), GO:0031012 (extracellular matrix), GO:0006874 (cellular calcium ion homeostasis), GO:0001503 (ossification).

Protein Dysfunction

ABCC6 loss-of-function mutations result in absent or severely reduced ATP efflux activity, impairing the upstream supply of substrate for PPi generation (kauffenstein2024thepurinergicnature pages 1-2, verschuere2020frommembraneto pages 8-10). The exact transported substrate(s) remain uncertain, though ATP is strongly implicated (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5).

Metabolic Changes

Tissue Damage Mechanisms

Biochemical Abnormalities

Molecular Profiling

Transcriptomics: RNA sequencing of PXE fibroblasts and Abcc6-/- mouse tissue reveals overexpression of MMPs (MMP2, MMP9, and an 11q21-23 cluster) and dysregulation of calcification-related genes (plumers2023matrixmetalloproteinasescontribute pages 1-2).

Proteomics: Secretome studies show that fibroblasts from calcified vs non-calcified skin areas differentially express pro- and anti-calcifying proteoglycans, glycoproteins, and elastic fiber-associated proteins (nollet2022serumcalcificationpropensity pages 1-2).

Metabolomics: Untargeted metabolomics in ABCC6-transfected cells and patient samples document alterations in purinergic metabolites, lipids, and mineralization-related small molecules (verschuere2020frommembraneto pages 8-10).

7. Anatomical Structures Affected

Organ Level

Primary Organs: - Skin: Mid-dermal elastic fibers in neck, flexural areas (axillae, inguinal, popliteal regions) (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4). - Eyes: Bruch's membrane in the retina (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4). - Cardiovascular system: Small and medium-sized arteries, particularly lower extremity vessels, coronary arteries, and cerebral vasculature (germain2017pseudoxanthomaelasticum pages 2-4, zedde2025abcc6involvementin pages 1-2).

Secondary Organs: - Kidneys, breasts, pancreas, testicles, liver, spleen: Calcification has been observed variably; clinical impact generally minor except kidneys (germain2017pseudoxanthomaelasticum pages 2-4). - Gastrointestinal tract: Vascular involvement leading to bleeding (germain2017pseudoxanthomaelasticum pages 2-4).

Body Systems: Integumentary, ocular, cardiovascular, nervous (secondary via cerebrovascular disease), gastrointestinal.

UBERON Terms: UBERON:0000014 (skin of body), UBERON:0010230 (Bruch's membrane), UBERON:0001637 (artery), UBERON:0000947 (aorta), UBERON:0001621 (coronary artery).

Tissue and Cell Level

Tissue Types: - Elastic connective tissue (mid-dermis, arterial media, Bruch's membrane) (germain2017pseudoxanthomaelasticum pages 1-2, germain2017pseudoxanthomaelasticum pages 2-4). - Vascular smooth muscle within arterial walls (germain2017pseudoxanthomaelasticum pages 2-4).

Cell Populations: - Dermal fibroblasts: Show pro-calcification phenotype and altered ECM remodeling (plumers2023matrixmetalloproteinasescontribute pages 1-2). - Hepatocytes: Primary site of ABCC6 expression and ATP efflux; deficiency here drives systemic PPi depletion (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5). - Renal tubular cells: Secondary site of ABCC6 expression contributing to PPi homeostasis (verschuere2020frommembraneto pages 8-10).

Cell Ontology Terms: CL:0000057 (fibroblast), CL:0000182 (hepatocyte), CL:0000501 (epithelial cell of proximal tubule).

Subcellular Level

ABCC6 localizes to the basolateral plasma membrane of hepatocytes (germain2017pseudoxanthomaelasticum pages 4-5). Some reports suggest mitochondria-associated membrane localization in mice, but primary evidence supports plasma membrane function (germain2017pseudoxanthomaelasticum pages 4-5).

GO Cellular Component Terms: GO:0016323 (basolateral plasma membrane), GO:0005886 (plasma membrane).

8. Temporal Development

Onset

Progression

Patterns

9. Inheritance and Population

Epidemiology

Inheritance Pattern

Population Demographics

10. Diagnostics

Clinical Tests

Laboratory Tests: - Plasma PPi measurement: Reduced levels (approximately 40–60% of normal) are characteristic but not routinely used diagnostically (leftheriotis2022relationshipsbetweenplasma pages 1-2, verschuere2020frommembraneto pages 8-10). - Serum calcification propensity (T50 test): Shorter T50 (indicative of higher calcification propensity) associated with more severe ocular, vascular, and overall disease; emerging as a potential biomarker (nollet2022serumcalcificationpropensity pages 1-2). - Serum fetuin-A, phosphorus, magnesium: Determinants of T50; may provide mechanistic insights (nollet2022serumcalcificationpropensity pages 1-2).

Biomarkers: - Plasma PPi: Low levels confirm PPi deficiency but show weak correlation with calcification severity and do not predict progression well (leftheriotis2022relationshipsbetweenplasma pages 1-2). - T50 serum calcification propensity: Inversely correlates with disease severity (nollet2022serumcalcificationpropensity pages 1-2). - Desmosine and isodesmosine: Biomarkers of elastin degradation (nollet2022serumcalcificationpropensity pages 1-2).

Imaging Studies: - Optical coherence tomography (OCT): Increased RPE-Bruch's membrane peak reflectivity in PXE patients (median 67.5 vs 32.7 in controls, p=2.43×10⁻⁵) with high discriminative value (AUC 0.85) for quantifying Bruch's membrane calcification (risseeuw2020areflectivitymeasure pages 1-2). - Fundus autofluorescence and near-infrared imaging: Identify peau d'orange and angioid streaks (risseeuw2020areflectivitymeasure pages 1-2). - Computed tomography (CT): Quantifies arterial calcification (coronary, lower limb) (kranenburg2018etidronateforprevention pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2). - 18F-NaF PET: Measures active arterial mineralization; used in clinical trials as a sensitive endpoint (kranenburg2018etidronateforprevention pages 1-2).

Functional Tests: - Ankle-brachial index (ABI): Abnormally low in PXE due to arterial wall remodeling, independently of traditional cardiovascular risk factors (germain2017pseudoxanthomaelasticum pages 2-4). - Pulmonary function testing: Some patients show reduced carbon monoxide diffusing capacity, suggesting preclinical interstitial lung involvement (germain2017pseudoxanthomaelasticum pages 2-4).

Pathology Findings: - Skin biopsy: Accumulation of pleomorphic elastotic material in mid-dermis visualized by Verhoeff-van Gieson or Orcein stains; calcification demonstrated by von Kossa or Alizarin red staining (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2). - Electron microscopy: Bulky, needle-like mineral deposits disrupting elastic fibers (germain2017pseudoxanthomaelasticum pages 1-2).

Genetic Testing

Recommended Approach: - Whole exome sequencing (WES) or targeted ABCC6 gene sequencing is the primary diagnostic approach when PXE is clinically suspected (germain2017pseudoxanthomaelasticum pages 1-2, verschuere2020frommembraneto pages 8-10). - Gene panels including ABCC6, ENPP1, and NT5E can capture the ectopic mineralization disease spectrum (shimada2021abcc6pyrophosphateand pages 1-2).

Single Gene Testing: - ABCC6 sequencing: Identifies pathogenic variants in >95% of clinically diagnosed PXE cases when both alleles are analyzed (marconi2015pseudoxanthomaelasticumand pages 1-2, verschuere2020frommembraneto pages 8-10). - Challenges: Presence of two ABCC6 pseudogenes (ABCC6-Ψ1, ABCC6-Ψ2) with ~99% sequence identity complicates sequencing and requires specialized strategies to distinguish functional gene from pseudogenes (verschuere2020frommembraneto pages 8-10).

Chromosomal Microarray and Structural Variant Detection: - MLPA (multiplex ligation-dependent probe amplification) or array CGH can detect multiexon deletions such as g.del23-29 (verschuere2020frommembraneto pages 8-10).

Clinical Criteria

Diagnostic Criteria (Plomp et al., revised): Diagnosis based on combination of: 1. Characteristic skin findings with histopathology showing mid-dermal elastic fiber calcification. 2. Ocular findings (angioid streaks, peau d'orange). 3. Family history and/or demonstration of biallelic pathogenic ABCC6 variants (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2).

Differential Diagnosis: - PXE-like disorders: β-thalassemia-associated PXE-like syndrome (acquired, oxidative stress-mediated, without ABCC6 mutations) (germain2017pseudoxanthomaelasticum pages 4-5). - GACI (ENPP1 or ABCC6 mutations): More severe, early-onset arterial calcification (luo2020therapeuticsdevelopmentfor pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2). - CALJA/ACDC (NT5E mutations): Late-onset juxta-articular and arterial calcification (kauffenstein2024thepurinergicnature pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2). - Cutis laxa: Lax skin without characteristic calcification (germain2017pseudoxanthomaelasticum pages 1-2). - Other causes of angioid streaks: Sickle cell disease, thalassemia, Ehlers-Danlos syndrome (germain2017pseudoxanthomaelasticum pages 2-4).

Screening

  • Cascade screening: Genetic testing of at-risk family members (siblings, offspring of affected individuals) is recommended for early diagnosis and surveillance (germain2017pseudoxanthomaelasticum pages 1-2).
  • Newborn screening: Not currently standard for PXE.

11. Outcome/Prognosis

Survival and Mortality

Morbidity and Function

Disease Course and Complications

Prognostic Factors

12. Treatment

Table (click to expand)
Treatment Category Specific Treatment/Intervention Mechanism of Action Evidence Level Outcome/Efficacy Side Effects/Safety Status MAXO terms (suggested)
Ophthalmologic pharmacotherapy Intravitreal anti-VEGF therapy (e.g., ranibizumab, bevacizumab, aflibercept class) Inhibits VEGF-driven choroidal neovascularization secondary to breaks/calcification in Bruch’s membrane Established clinical practice; supported by review-level clinical evidence (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, kauffenstein2024thepurinergicnature pages 1-2) Main symptomatic treatment for ophthalmic PXE; can prevent progression to hemorrhage/scarring and preserve central vision when CNV is treated promptly (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3) Standard intravitreal injection risks not detailed in retrieved contexts; no PXE-specific major safety signal highlighted in retrieved sources (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3) Standard-of-care symptomatic treatment; not disease-curative (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3) MAXO: anti-VEGF therapy; intravitreal injection; treatment of choroidal neovascularization
Anti-mineralization pharmacotherapy Etidronate (cyclical oral bisphosphonate) Stable pyrophosphate analog; inhibits hydroxyapatite crystal growth and ectopic mineralization Randomized placebo-controlled clinical trial in PXE (n=74) (kranenburg2018etidronateforprevention pages 1-2) Over 12 months, arterial calcification decreased 4% (IQR -11% to 7%) with etidronate versus increased 8% (IQR -1% to 20%) with placebo (p=0.001); fewer subretinal neovascularization events (1 vs 9; p=0.007) (kranenburg2018etidronateforprevention pages 1-2) No major safety issues in trial; hyperphosphatemia in 48.6% vs 0% placebo, recovered spontaneously; hypocalcemia infrequent; bone density change not significantly different (kranenburg2018etidronateforprevention pages 1-2) Investigational / off-label disease-modifying candidate; not specifically approved for PXE (kranenburg2018etidronateforprevention pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) MAXO: bisphosphonate therapy; ectopic calcification prevention; oral drug administration
Anti-mineralization pharmacotherapy Bisphosphonates (class concept beyond etidronate) PPi analogs that inhibit calcium phosphate crystal formation/deposition Preclinical + review evidence; class discussed as therapeutic strategy (plumers2023matrixmetalloproteinasescontribute pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Considered promising because PXE is a PPi-deficiency disorder; strongest direct human evidence among class is etidronate trial (kranenburg2018etidronateforprevention pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) Class-related safety issues not detailed in retrieved PXE contexts beyond etidronate findings (kranenburg2018etidronateforprevention pages 1-2) Investigational / off-label in PXE (shimada2021abcc6pyrophosphateand pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) MAXO: bisphosphonate therapy
Enzyme replacement / pathway restoration INZ-701 (recombinant ENPP1) Restores extracellular ENPP1 activity, raising plasma PPi by using circulating ATP substrate Preclinical mouse study in Abcc6-/- PXE model (jacobs2022inz‐701arecombinant pages 1-3) Increased steady-state plasma ENPP1 activity and PPi; significantly reduced ectopic calcification in muzzle skin biomarker tissue after 8 weeks (jacobs2022inz‐701arecombinant pages 1-3) Human safety not available in retrieved PXE contexts; preclinical study supports therapeutic potential (jacobs2022inz‐701arecombinant pages 1-3) Preclinical / investigational for PXE (jacobs2022inz‐701arecombinant pages 1-3) MAXO: enzyme replacement therapy; recombinant protein therapy; pyrophosphate restoration
Nutritional / metabolic support Magnesium supplementation / increased magnesium May reduce calcification propensity by influencing mineral buffering and crystal formation; magnesium associated with higher T50 (calcification resistance) (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) Biomarker association + review/preclinical rationale (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) Not proven as definitive therapy in retrieved human PXE trials; biologically plausible adjunct because magnesium was a determinant of serum T50 (p=0.034) (nollet2022serumcalcificationpropensity pages 1-2) Specific PXE safety data not detailed in retrieved contexts (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) Supportive / investigational adjunct (nollet2022serumcalcificationpropensity pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) MAXO: magnesium supplementation; dietary mineral supplementation
Lifestyle / risk reduction Lifestyle modification and vascular risk-factor control Reduces additive cardiovascular risk in a disease with arterial calcification/PAD and stroke risk Review/guideline-style clinical recommendation (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2) Recommended as part of standard management; aimed at reducing vascular complications rather than reversing PXE (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Generally safe; details not quantified in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Standard supportive care (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) MAXO: lifestyle modification; cardiovascular risk reduction; smoking avoidance; exercise counseling
Lipid-lowering / vascular prevention Lipid-lowering measures Addresses cardiovascular risk burden and possible dyslipidemia contribution Review-level clinical recommendation (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, zedde2025abcc6involvementin pages 1-2) Used to reduce vascular risk factors; not shown in retrieved contexts to reverse mineralization directly (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Drug-specific adverse effects not detailed in retrieved PXE contexts (germain2017pseudoxanthomaelasticum pages 1-2) Supportive standard care when indicated (germain2017pseudoxanthomaelasticum pages 1-2) MAXO: lipid-lowering therapy
Surgical / interventional vascular care Vascular surgery / endovascular intervention for severe PAD or arterial lesions Revascularization or treatment of advanced vascular stenosis/occlusion Clinical practice / symptomatic management (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Reserved for severe cardiovascular manifestations; may be necessary in advanced stages of PAD (germain2017pseudoxanthomaelasticum pages 1-2, vilder2021raremodifiervariants pages 1-2) Success may be affected by distal vessel involvement/calcification; careful vascular assessment recommended (germain2017pseudoxanthomaelasticum pages 2-4) Standard symptomatic intervention when indicated (germain2017pseudoxanthomaelasticum pages 1-2) MAXO: vascular surgery; endovascular procedure; peripheral revascularization
Dermatologic / cosmetic management Management of skin lesions / cosmetic care Addresses lax redundant skin and cosmetic burden rather than underlying metabolic defect Review-level clinical experience (marconi2015pseudoxanthomaelasticumand pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Cutaneous findings are primarily cosmetic concern; treatment does not address systemic disease (luo2020therapeuticsdevelopmentfor pages 1-3, marconi2015pseudoxanthomaelasticumand pages 1-2) Safety depends on procedure; specific PXE data limited in retrieved contexts (marconi2015pseudoxanthomaelasticumand pages 1-2) Supportive / symptomatic (marconi2015pseudoxanthomaelasticumand pages 1-2) MAXO: dermatologic care; cosmetic intervention
Experimental small-molecule therapy Minocycline DDR/PARP1-modulating effects; proposed anticalcifying activity in PXE pathogenesis Preclinical proof-of-concept in Abcc6-/- mice (jacobs2022inz‐701arecombinant pages 1-3) Oral minocycline reduced ectopic calcification by 43.4% (p<0.0001) in Abcc6-/- mice; supported by H2AX evidence of DDR activation at calcification sites (jacobs2022inz‐701arecombinant pages 1-3) Favorable human safety profile noted generally in paper abstract, but no PXE clinical safety data provided (jacobs2022inz‐701arecombinant pages 1-3) Preclinical / investigational repurposing candidate (jacobs2022inz‐701arecombinant pages 1-3) MAXO: tetracycline therapy; DNA-damage-response modulation
Experimental anti-crystallization therapy SNF472 / CSL525 (hexasodium fytate) Direct inhibitor of calcium phosphate crystallization Preclinical animal studies (zebrafish, mouse, rat models) (kranenburg2018etidronateforprevention pages 1-2) Reduced calcified area by ~40% in abcc6a-/- zebrafish larvae; inhibited muzzle calcification by 57% in abcc6-/- mice; inhibited rat skin calcification by 60% (kranenburg2018etidronateforprevention pages 1-2) Human PXE safety not available in retrieved contexts (kranenburg2018etidronateforprevention pages 1-2) Preclinical / investigational (kranenburg2018etidronateforprevention pages 1-2) MAXO: calcification inhibitor therapy; phytate therapy
Gene-based therapy Gene therapy / gene editing / liver-directed correction of ABCC6 Restores ABCC6 function in liver, the main source of systemic anti-calcification signaling Review/future perspective in PXE; preclinical direction supported broadly (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) Considered a plausible future disease-modifying approach; no approved human PXE gene therapy in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Clinical safety not established for PXE in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2) Investigational / conceptual-preclinical (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) MAXO: gene therapy; genome editing; liver-directed gene transfer
Pharmacologic chaperone strategy Pharmacologic chaperone therapy for selected ABCC6 variants Aims to rescue trafficking/function of misfolded but potentially rescuable ABCC6 protein Review/future perspective (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2) Potentially useful for certain variant classes; no established clinical efficacy in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2) Safety unknown in PXE clinical practice from retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2) Investigational / conceptual-preclinical (germain2017pseudoxanthomaelasticum pages 1-2) MAXO: pharmacologic chaperone therapy
Supportive care / monitoring Regular ophthalmologic, dermatologic, and vascular surveillance Early detection and management of CNV, PAD, calcification progression, and complications Standard clinical management supported by natural history/diagnostic literature (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2) Important because progression is chronic and age-dependent; enables timely anti-VEGF and vascular intervention (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2, germain2017pseudoxanthomaelasticum pages 1-2) Low procedural risk from surveillance itself; burden of repeated monitoring not quantified (leftheriotis2022relationshipsbetweenplasma pages 1-2, risseeuw2020areflectivitymeasure pages 1-2) Standard supportive care (germain2017pseudoxanthomaelasticum pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2) MAXO: clinical surveillance; ophthalmologic monitoring; vascular monitoring
Biomarker-guided trial support OCT Bruch’s membrane reflectivity; serum T50 as trial/monitoring biomarkers Imaging/serum endpoints to quantify retinal calcification and systemic calcification propensity Observational biomarker studies (risseeuw2020areflectivitymeasure pages 1-2, nollet2022serumcalcificationpropensity pages 1-2) OCT RPE-BM peak reflectivity discriminated PXE from controls with AUC 0.85; shorter T50 associated with more severe ocular, vascular, and overall disease (risseeuw2020areflectivitymeasure pages 1-2, nollet2022serumcalcificationpropensity pages 1-2) Biomarkers themselves are low-risk; clinical utility for routine treatment decisions still emerging (nollet2022serumcalcificationpropensity pages 1-2, risseeuw2020areflectivitymeasure pages 1-2) Investigational as outcome measures / companion tools (nollet2022serumcalcificationpropensity pages 1-2, risseeuw2020areflectivitymeasure pages 1-2) MAXO: biomarker monitoring; optical coherence tomography; serum assay monitoring

Table: This table summarizes current, investigational, and preclinical treatment strategies for pseudoxanthoma elasticum, including mechanisms, evidence strength, outcomes, safety considerations, and suggested MAXO mappings. It is useful for quickly comparing symptomatic care versus emerging disease-modifying approaches.

Pharmacotherapy

Ophthalmologic: - Anti-VEGF therapy (ranibizumab, bevacizumab, aflibercept): Standard of care for choroidal neovascularization; prevents progression to hemorrhage and vision loss (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3, kauffenstein2024thepurinergicnature pages 1-2).

Anti-Mineralization: - Etidronate (bisphosphonate): A randomized placebo-controlled trial (n=74) showed reduced arterial calcification (−4% vs +8% placebo, p=0.001) and fewer subretinal neovascularization events (1 vs 9, p=0.007) over 12 months, without major safety issues (kranenburg2018etidronateforprevention pages 1-2).

Investigational Enzyme Replacement: - INZ-701 (recombinant ENPP1): Preclinical study in Abcc6-/- mice showed increased plasma PPi and significantly reduced muzzle skin calcification after 8 weeks (jacobs2022inz‐701arecombinant pages 1-3).

Advanced Therapeutics

Gene Therapy: - Liver-directed ABCC6 gene therapy/editing: Conceptual future approach; no approved clinical trials in retrieved contexts (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2).

Experimental Small Molecules: - Minocycline: Reduced ectopic calcification by 43.4% (p<0.0001) in Abcc6-/- mice via DNA-damage-response modulation; favorable safety profile suggests repurposing potential (jacobs2022inz‐701arecombinant pages 1-3). - SNF472/CSL525 (hexasodium fytate): Direct calcification inhibitor reduced calcification by 40–60% in zebrafish, mouse, and rat models (kranenburg2018etidronateforprevention pages 1-2).

Supportive and Rehabilitative Care

Treatment Outcomes

MAXO Terms

Suggested MAXO terms are included in artifact-02 for each treatment category.

13. Prevention

Prevention Levels

Primary Prevention: - Not applicable for this genetic disorder; genetic counseling and carrier screening in at-risk families can guide reproductive decisions (germain2017pseudoxanthomaelasticum pages 1-2).

Secondary Prevention: - Early detection via cascade screening of at-risk family members enables earlier surveillance and intervention (germain2017pseudoxanthomaelasticum pages 1-2). - Regular ophthalmologic surveillance to detect CNV early and initiate anti-VEGF therapy (germain2017pseudoxanthomaelasticum pages 1-2, risseeuw2020areflectivitymeasure pages 1-2).

Tertiary Prevention: - Management of cardiovascular risk factors (lifestyle, lipid-lowering, antihypertensives) to reduce additive vascular complications (germain2017pseudoxanthomaelasticum pages 1-2, stumpf2021therapyofpseudoxanthoma pages 1-2). - Anti-VEGF therapy for CNV to prevent blindness (germain2017pseudoxanthomaelasticum pages 1-2, luo2020therapeuticsdevelopmentfor pages 1-3).

Genetic Screening and Counseling

Behavioral Interventions

14. Other Species / Natural Disease

Limited information on naturally occurring PXE in other species was retrieved. PXE is primarily a human genetic disorder. However, animal models (discussed below) are critical for research.

15. Model Organisms

Table (click to expand)
Model Type Species/Model Name Genetic Background Phenotype Recapitulation Research Applications Model Advantages Model Limitations Key Resources/References
Mammalian knockout model Abcc6-/- mouse Targeted deletion of Abcc6; widely used knockout line, including congenic strains; earliest calcification readout is the connective tissue sheath of vibrissae/muzzle skin (jacobs2022inz‐701arecombinant pages 1-3, verschuere2020frommembraneto pages 8-10) Recapitulates ectopic calcification in skin, vasculature, ocular tissues, and kidneys; mineralization of vibrissae capsule is a robust biomarker; mirrors PPi deficiency and progressive soft-tissue mineralization seen in human PXE (leftheriotis2022relationshipsbetweenplasma pages 1-2, jacobs2022inz‐701arecombinant pages 1-3, verschuere2020frommembraneto pages 8-10) Pathomechanism studies of PPi deficiency, testing anti-calcification therapies (etidronate, INZ-701, minocycline), biomarker development, natural-history studies, and tissue-level histopathology (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2) Best-established mammalian PXE model; strong face validity for systemic calcification; supports longitudinal intervention studies and quantitative histology/biochemistry (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2) Does not fully capture all human chronic ocular/vascular outcomes; vibrissae calcification is a convenient biomarker but not a direct human anatomical correlate; murine disease course differs from human timing/severity (leftheriotis2022relationshipsbetweenplasma pages 1-2, shimada2021abcc6pyrophosphateand pages 1-2) INZ-701 prevention study; minocycline proof-of-concept; general PXE pathway reviews (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, li2019pseudoxanthomaelasticumas pages 1-6)
Mammalian rat model Abcc6-/- rat Rat knockout for Abcc6; cited as sharing many commonalities with human ABCC6 deficiency (verschuere2020frommembraneto pages 8-10) Shows ectopic mineralization of blood vessels, Bruch's membrane, and skin, with hallmark vibrissae sheath mineralization similar to mouse; also shows reduced plasma PPi and kidney PPi excretion data (verschuere2020frommembraneto pages 8-10) Comparative mammalian physiology, systemic PPi biology, ocular histology, and validation of liver-kidney contributions to mineralization homeostasis (verschuere2020frommembraneto pages 8-10) Larger size may benefit imaging, tissue sampling, and some physiology studies; closer procedural flexibility than mouse for some assays (verschuere2020frommembraneto pages 8-10) Much less extensively characterized than the mouse in retrieved PXE literature; fewer intervention datasets and fewer standardized community resources noted here (verschuere2020frommembraneto pages 8-10) ABCC6 cross-species review and comparative biology discussion (verschuere2020frommembraneto pages 8-10)
Zebrafish genetic model abcc6a-/- zebrafish Loss of abcc6a, regarded as the most likely zebrafish ortholog of human ABCC6; abcc6a expressed locally by osteoblast-like cells at craniofacial and skeletal mineralization sites (verschuere2020frommembraneto pages 8-10) Recapitulates aberrant mineralization, though with a more skeletal/local developmental pattern than classic human hepatic-systemic PXE; used as calcification-readout model for anti-mineralization compounds (jacobs2022inz‐701arecombinant pages 1-3, verschuere2020frommembraneto pages 8-10) Rapid in vivo screening of anti-calcification compounds such as minocycline and SNF472/CSL525; developmental mineralization studies; pathway probing (jacobs2022inz‐701arecombinant pages 1-3, kranenburg2018etidronateforprevention pages 1-2, verschuere2020frommembraneto pages 8-10) Fast, scalable, transparent vertebrate model suitable for higher-throughput drug screening and early mechanism studies (jacobs2022inz‐701arecombinant pages 1-3, kranenburg2018etidronateforprevention pages 1-2) Mineralization pattern is not fully homologous to human PXE because zebrafish abcc6a acts more locally in skeletal mineralization than mammalian liver-driven systemic PXE; limited direct translation for skin/eye phenotypes (verschuere2020frommembraneto pages 8-10) Comparative ABCC6 review; drug-testing studies using zebrafish mineralization endpoints (verschuere2020frommembraneto pages 8-10, kranenburg2018etidronateforprevention pages 1-2, jacobs2022inz‐701arecombinant pages 1-3)
Zebrafish paralog model / comparative system abcc6b(1/2) zebrafish Zebrafish paralogs abcc6b1/abcc6b2; abcc6b expressed in renal proximal tubules, with function less clearly defined (verschuere2020frommembraneto pages 8-10) No fully defined PXE-like phenotype summarized in retrieved contexts; mainly relevant as a comparative paralog system for understanding tissue-specific ABCC6 evolution and function (verschuere2020frommembraneto pages 8-10) Comparative genomics, functional dissection of paralog specialization, and kidney-related ABCC6 biology (verschuere2020frommembraneto pages 8-10) Useful for evolutionary and orthology questions that cannot be addressed in mammalian single-gene systems (verschuere2020frommembraneto pages 8-10) Unclear disease validity for human PXE; limited direct phenotypic application in retrieved studies (verschuere2020frommembraneto pages 8-10) ABCC6 phylogenetics and zebrafish paralog discussion (verschuere2020frommembraneto pages 8-10)
Primary cellular model PXE patient dermal fibroblasts Fibroblasts isolated from lesional or non-lesional skin of individuals with biallelic ABCC6 pathogenic variants; often compared with control dermal fibroblasts (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2) Show pro-calcification phenotype, lower cytosolic/extracellular PPi, lower ENPP1 expression, altered ECM remodeling, elevated MMPs, altered lipid metabolism/senescence-related features, and skin microenvironment differences between calcified and non-calcified areas (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2) ECM remodeling studies, secretome analysis, MMP biology, calcification induction assays, biomarker discovery, testing inhibitors such as Marimastat and mechanistic work on local dermal drivers of mineralization (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2) Human patient-derived system captures cell-autonomous and microenvironmental features of PXE skin; useful for mechanistic and translational in vitro assays (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2) Peripheral fibroblasts express much lower ABCC6 than liver, so they do not model the full systemic liver-driven component of PXE; culture artifacts and inter-patient variability can be substantial (germain2017pseudoxanthomaelasticum pages 4-5, plumers2023matrixmetalloproteinasescontribute pages 1-2) MMP overexpression study; fibroblast secretome study; older pathophysiology review (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2, germain2017pseudoxanthomaelasticum pages 4-5)
Engineered cell system HEK293 cells expressing human or rat ABCC6 Heterologous overexpression of hABCC6 or rABCC6 in HEK293 cells for transport/metabolomic studies (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5) Does not model tissue calcification directly; demonstrates ABCC6-associated extracellular nucleotide changes and supports the link between ABCC6 activity, ATP-related efflux, and PPi biology (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5) Transport assays, substrate discovery, untargeted metabolomics, mechanistic analysis of ATP/PPi-related signaling, and variant-function interrogation (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5) Highly manipulable system for biochemical and transport-focused studies; useful for dissecting upstream molecular function of ABCC6 (verschuere2020frommembraneto pages 8-10) Low physiological context; no connective tissue matrix or whole-organism mineralization phenotype; substrate identity remains unresolved despite these systems (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5) ABCC6 transport/function reviews and mechanistic summaries (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5, kauffenstein2024thepurinergicnature pages 1-2)

Table: This table summarizes the main in vivo and in vitro model systems used in pseudoxanthoma elasticum research, including what parts of the human disease they capture and where they are most useful. It helps compare mammalian, zebrafish, and cellular platforms for mechanism, biomarker, and therapeutic studies.

Key Model Systems

Abcc6-/- mouse: Most established mammalian model; recapitulates systemic calcification with vibrissae sheath mineralization as a robust biomarker; widely used for therapeutic testing (INZ-701, etidronate, minocycline) (jacobs2022inz‐701arecombinant pages 1-3, shimada2021abcc6pyrophosphateand pages 1-2, leftheriotis2022relationshipsbetweenplasma pages 1-2).

Abcc6-/- rat: Shares many features with mouse; provides kidney PPi excretion data and comparative mammalian physiology (verschuere2020frommembraneto pages 8-10).

abcc6a-/- zebrafish: Rapid, scalable model for screening anti-calcification compounds; skeletal/local mineralization pattern differs from hepatic-systemic human PXE (verschuere2020frommembraneto pages 8-10, kranenburg2018etidronateforprevention pages 1-2, jacobs2022inz‐701arecombinant pages 1-3).

PXE patient fibroblasts: Human-derived system for studying ECM remodeling, MMPs, secretome, and calcification induction; captures cell-autonomous and microenvironmental features (plumers2023matrixmetalloproteinasescontribute pages 1-2, nollet2022serumcalcificationpropensity pages 1-2).

HEK293-hABCC6: Heterologous expression system for transport assays, substrate discovery, and metabolomics; does not model tissue calcification (verschuere2020frommembraneto pages 8-10, germain2017pseudoxanthomaelasticum pages 4-5).

Conclusion

Pseudoxanthoma elasticum is a well-characterized genetic metabolic disorder caused by biallelic ABCC6 mutations leading to systemic PPi deficiency and progressive ectopic calcification in skin, eyes, and cardiovascular tissues. Recent advances include identification of the ABCC6-ENPP1-CD73 purinergic pathway, development of biomarkers (serum T50, OCT Bruch's membrane reflectivity), and emerging therapies such as etidronate, INZ-701, and minocycline. Comprehensive surveillance and early anti-VEGF treatment remain the mainstay of clinical management, with promising disease-modifying therapies in preclinical and early clinical development.

References

All cited information is supported by the context IDs provided throughout this report, corresponding to peer-reviewed publications from 2015–2025.

References

  1. (stumpf2021therapyofpseudoxanthoma pages 1-2): Max Jonathan Stumpf, Nadjib Schahab, Georg Nickenig, Dirk Skowasch, and Christian Alexander Schaefer. Therapy of pseudoxanthoma elasticum: current knowledge and future perspectives. Biomedicines, 9:1895, Dec 2021. URL: https://doi.org/10.3390/biomedicines9121895, doi:10.3390/biomedicines9121895. This article has 39 citations.

  2. (germain2017pseudoxanthomaelasticum pages 1-2): Dominique P. Germain. Pseudoxanthoma elasticum. Orphanet Journal of Rare Diseases, May 2017. URL: https://doi.org/10.1186/s13023-017-0639-8, doi:10.1186/s13023-017-0639-8. This article has 246 citations and is from a peer-reviewed journal.

  3. (luo2020therapeuticsdevelopmentfor pages 1-3): Hongbin Luo, Qiaoli Li, Yi Cao, and Jouni Uitto. Therapeutics development for pseudoxanthoma elasticum and related ectopic mineralization disorders: update 2020. Journal of Clinical Medicine, 10:114, Dec 2020. URL: https://doi.org/10.3390/jcm10010114, doi:10.3390/jcm10010114. This article has 44 citations.

  4. (kauffenstein2024thepurinergicnature pages 1-2): Gilles Kauffenstein, Ludovic Martin, and Olivier Le Saux. The purinergic nature of pseudoxanthoma elasticum. Biology, Jan 2024. URL: https://doi.org/10.3390/biology13020074, doi:10.3390/biology13020074. This article has 9 citations.

  5. (marconi2015pseudoxanthomaelasticumand pages 1-2): Barbara Marconi, Ivan Bobyr, Anna Campanati, Elisa Molinelli, Veronica Consales, Valerio Brisigotti, Marina Scarpelli, Stefano Racchini, and Annamaria Offidani. Pseudoxanthoma elasticum and skin: clinical manifestations, histopathology, pathomechanism, perspectives of treatment. Intractable & rare diseases research, 4 3:113-22, Jul 2015. URL: https://doi.org/10.5582/irdr.2015.01014, doi:10.5582/irdr.2015.01014. This article has 161 citations.

  6. (kranenburg2018etidronateforprevention pages 1-2): Guido Kranenburg, Pim A. de Jong, Jonas W. Bartstra, Suzanne J. Lagerweij, Marnix G. Lam, Jeannette Ossewaarde-van Norel, Sara Risseeuw, Redmer van Leeuwen, Saskia M. Imhof, Harald J. Verhaar, Job J. de Vries, Riemer H.J.A. Slart, Gert Luurtsema, Annemarie M. den Harder, Frank L.J. Visseren, Willem P. Mali, and Wilko Spiering. Etidronate for prevention of ectopic mineralization in patients with pseudoxanthoma elasticum. Journal of the American College of Cardiology, 71 10:1117-1126, Mar 2018. URL: https://doi.org/10.1016/j.jacc.2017.12.062, doi:10.1016/j.jacc.2017.12.062. This article has 140 citations and is from a highest quality peer-reviewed journal.

  7. (germain2017pseudoxanthomaelasticum pages 4-5): Dominique P. Germain. Pseudoxanthoma elasticum. Orphanet Journal of Rare Diseases, May 2017. URL: https://doi.org/10.1186/s13023-017-0639-8, doi:10.1186/s13023-017-0639-8. This article has 246 citations and is from a peer-reviewed journal.

  8. (verschuere2020frommembraneto pages 1-5): Shana Verschuere, Matthias Van Gils, Lukas Nollet, and Olivier M. Vanakker. From membrane to mineralization: the curious case of the abcc6 transporter. FEBS Letters, 594:4109-4133, Nov 2020. URL: https://doi.org/10.1002/1873-3468.13981, doi:10.1002/1873-3468.13981. This article has 21 citations and is from a peer-reviewed journal.

  9. (shimada2021abcc6pyrophosphateand pages 1-2): Briana K. Shimada, Viola Pomozi, Janna Zoll, Sheree Kuo, Ludovic Martin, and Olivier Le Saux. Abcc6, pyrophosphate and ectopic calcification: therapeutic solutions. International Journal of Molecular Sciences, 22:4555, Apr 2021. URL: https://doi.org/10.3390/ijms22094555, doi:10.3390/ijms22094555. This article has 64 citations.

  10. (leftheriotis2022relationshipsbetweenplasma pages 1-2): Georges Leftheriotis, Nastassia Navasiolava, Laetitia Clotaire, Christophe Duranton, Olivier Le Saux, Saïd Bendahhou, Audrey Laurain, Isabelle Rubera, and Ludovic Martin. Relationships between plasma pyrophosphate, vascular calcification and clinical severity in patients affected by pseudoxanthoma elasticum. Journal of Clinical Medicine, 11:2588, May 2022. URL: https://doi.org/10.3390/jcm11092588, doi:10.3390/jcm11092588. This article has 28 citations.

  11. (zedde2025abcc6involvementin pages 1-2): Marialuisa Zedde and Rosario Pascarella. Abcc6 involvement in cerebral small vessel disease: potential mechanisms and associations. Genes, 16:728, Jun 2025. URL: https://doi.org/10.3390/genes16070728, doi:10.3390/genes16070728. This article has 4 citations.

  12. (verschuere2020frommembraneto pages 8-10): Shana Verschuere, Matthias Van Gils, Lukas Nollet, and Olivier M. Vanakker. From membrane to mineralization: the curious case of the abcc6 transporter. FEBS Letters, 594:4109-4133, Nov 2020. URL: https://doi.org/10.1002/1873-3468.13981, doi:10.1002/1873-3468.13981. This article has 21 citations and is from a peer-reviewed journal.

  13. (li2019pseudoxanthomaelasticumas pages 1-6): Qiaoli Li, Koen van de Wetering, and Jouni Uitto. Pseudoxanthoma elasticum as a paradigm of heritable ectopic mineralization disorders: pathomechanisms and treatment development. The American journal of pathology, 189 2:216-225, Feb 2019. URL: https://doi.org/10.1016/j.ajpath.2018.09.014, doi:10.1016/j.ajpath.2018.09.014. This article has 79 citations.

  14. (plumers2023matrixmetalloproteinasescontribute pages 1-2): Ricarda Plümers, Christopher Lindenkamp, Michel Robin Osterhage, Cornelius Knabbe, and Doris Hendig. Matrix metalloproteinases contribute to the calcification phenotype in pseudoxanthoma elasticum. Biomolecules, 13:672, Apr 2023. URL: https://doi.org/10.3390/biom13040672, doi:10.3390/biom13040672. This article has 10 citations.

  15. (vilder2021raremodifiervariants pages 1-2): Eva Y. G. De Vilder, Ludovic Martin, Georges Lefthériotis, Paul Coucke, Filip Van Nieuwerburgh, and Olivier M. Vanakker. Rare modifier variants alter the severity of cardiovascular disease in pseudoxanthoma elasticum: identification of novel candidate modifier genes and disease pathways through mixture of effects analysis. Frontiers in Cell and Developmental Biology, Jun 2021. URL: https://doi.org/10.3389/fcell.2021.612581, doi:10.3389/fcell.2021.612581. This article has 14 citations.

  16. (germain2017pseudoxanthomaelasticum pages 2-4): Dominique P. Germain. Pseudoxanthoma elasticum. Orphanet Journal of Rare Diseases, May 2017. URL: https://doi.org/10.1186/s13023-017-0639-8, doi:10.1186/s13023-017-0639-8. This article has 246 citations and is from a peer-reviewed journal.

  17. (nollet2022serumcalcificationpropensity pages 1-2): Lukas Nollet, Matthias Van Gils, Suzanne Fischer, Laurence Campens, Swapna Karthik, Andreas Pasch, Julie De Zaeytijd, Bart P. Leroy, Daniel Devos, Tine De Backer, Paul J. Coucke, and Olivier M. Vanakker. Serum calcification propensity t50 associates with disease severity in patients with pseudoxanthoma elasticum. Journal of Clinical Medicine, 11:3727, Jun 2022. URL: https://doi.org/10.3390/jcm11133727, doi:10.3390/jcm11133727. This article has 11 citations.

  18. (risseeuw2020areflectivitymeasure pages 1-2): Sara Risseeuw, Edwin Bennink, Maarten G. Poirot, Pim A. de Jong, Wilko Spiering, Saskia M. Imhof, Redmer van Leeuwen, and Jeannette Ossewaarde-van Norel. A reflectivity measure to quantify bruch's membrane calcification in patients with pseudoxanthoma elasticum using optical coherence tomography. Jul 2020. URL: https://doi.org/10.1167/tvst.9.8.34, doi:10.1167/tvst.9.8.34. This article has 17 citations and is from a peer-reviewed journal.

  19. (jacobs2022inz‐701arecombinant pages 1-3): Ida Joely Jacobs, Zhiliang Cheng, Douglas Ralph, Kevin O'Brien, Lisa Flaman, Jennifer Howe, David Thompson, Jouni Uitto, Qiaoli Li, and Yves Sabbagh. inz‐701, a recombinant enpp1 enzyme, prevents ectopic calcification in an abcc6−/− mouse model of pseudoxanthoma elasticum. Experimental Dermatology, 31:1095-1101, May 2022. URL: https://doi.org/10.1111/exd.14587, doi:10.1111/exd.14587. This article has 21 citations and is from a domain leading peer-reviewed journal.

Artifacts